Treatment of acute bacterial skin and skin structure infection with single-dose dalbavancin in persons who inject drugs
Background: Persons who inject drugs (PWID) are at increased risk of acute bacterial skin and skin structure infections (ABSSSIs), a growing healthcare concern. Multiple medical, social, and economic issues, including adherence and comorbidities, complicate the medical care of the PWID population, a...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BioExcel Publishing Ltd
2018-12-01
|
| Series: | Drugs in Context |
| Subjects: | |
| Online Access: | https://www.drugsincontext.com/treatment-of-acute-bacterial-skin-and-skin-structure-infection-with-single-dose-dalbavancin-in-persons-who-inject-drugs |
| _version_ | 1819076391709179904 |
|---|---|
| author | Pedro Luis Gonzalez Urania Rappo Karthik Akinapelli Jennifer S McGregor Sailaja Puttagunta Michael W Dunne |
| author_facet | Pedro Luis Gonzalez Urania Rappo Karthik Akinapelli Jennifer S McGregor Sailaja Puttagunta Michael W Dunne |
| author_sort | Pedro Luis Gonzalez |
| collection | DOAJ |
| description | Background: Persons who inject drugs (PWID) are at increased risk of acute bacterial skin and skin structure infections (ABSSSIs), a growing healthcare concern. Multiple medical, social, and economic issues, including adherence and comorbidities, complicate the medical care of the PWID population, adversely affecting patient outcomes.
Methods: We assessed demographics and outcomes for the PWID population in a double-blind trial of 698 patients randomized to dalbavancin 1500 mg as a single intravenous (IV) infusion or as a 2-dose regimen (1000 mg IV on day 1; 500 mg IV on day 8) for ABSSSI. The primary endpoint was ≥20% reduction in erythema at 48–72 hours in the intent-to-treat population; clinical status was also assessed at days 14 and 28.
Results: There were 212/698 (30.4%) patients with a history of injection drug use in this clinical trial. Dalbavancin efficacy was similar between the single- and 2-dose therapy groups in the PWID and non-PWID populations at all timepoints. Dalbavancin was well tolerated in the PWID population, with similar rates of adverse events as the non-PWID population.
Conclusion: Dalbavancin as a single-dose or 2-dose regimen had similar efficacy for the treatment of ABSSSI at all timepoints in the PWID and non-PWID populations. A single 30-minute IV infusion would eliminate the need for indwelling IV access. The convenience of a single dose supervised in a health setting may also optimize treatment adherence in the PWID population. |
| first_indexed | 2024-12-21T18:40:34Z |
| format | Article |
| id | doaj.art-3ecc525fb387486db854b4c900db82ae |
| institution | Directory Open Access Journal |
| issn | 1740-4398 1740-4398 |
| language | English |
| last_indexed | 2024-12-21T18:40:34Z |
| publishDate | 2018-12-01 |
| publisher | BioExcel Publishing Ltd |
| record_format | Article |
| series | Drugs in Context |
| spelling | doaj.art-3ecc525fb387486db854b4c900db82ae2022-12-21T18:54:01ZengBioExcel Publishing LtdDrugs in Context1740-43981740-43982018-12-01711010.7573/dic.212559Treatment of acute bacterial skin and skin structure infection with single-dose dalbavancin in persons who inject drugsPedro Luis GonzalezUrania Rappo Karthik AkinapelliJennifer S McGregor Sailaja PuttaguntaMichael W Dunne Background: Persons who inject drugs (PWID) are at increased risk of acute bacterial skin and skin structure infections (ABSSSIs), a growing healthcare concern. Multiple medical, social, and economic issues, including adherence and comorbidities, complicate the medical care of the PWID population, adversely affecting patient outcomes. Methods: We assessed demographics and outcomes for the PWID population in a double-blind trial of 698 patients randomized to dalbavancin 1500 mg as a single intravenous (IV) infusion or as a 2-dose regimen (1000 mg IV on day 1; 500 mg IV on day 8) for ABSSSI. The primary endpoint was ≥20% reduction in erythema at 48–72 hours in the intent-to-treat population; clinical status was also assessed at days 14 and 28. Results: There were 212/698 (30.4%) patients with a history of injection drug use in this clinical trial. Dalbavancin efficacy was similar between the single- and 2-dose therapy groups in the PWID and non-PWID populations at all timepoints. Dalbavancin was well tolerated in the PWID population, with similar rates of adverse events as the non-PWID population. Conclusion: Dalbavancin as a single-dose or 2-dose regimen had similar efficacy for the treatment of ABSSSI at all timepoints in the PWID and non-PWID populations. A single 30-minute IV infusion would eliminate the need for indwelling IV access. The convenience of a single dose supervised in a health setting may also optimize treatment adherence in the PWID population.https://www.drugsincontext.com/treatment-of-acute-bacterial-skin-and-skin-structure-infection-with-single-dose-dalbavancin-in-persons-who-inject-drugsdalbavancininfectious diseaseintravenousmethicillin-resistant Staphylococcus aureusskin infectionstaphylococcalsubstance abuse |
| spellingShingle | Pedro Luis Gonzalez Urania Rappo Karthik Akinapelli Jennifer S McGregor Sailaja Puttagunta Michael W Dunne Treatment of acute bacterial skin and skin structure infection with single-dose dalbavancin in persons who inject drugs Drugs in Context dalbavancin infectious disease intravenous methicillin-resistant Staphylococcus aureus skin infection staphylococcal substance abuse |
| title | Treatment of acute bacterial skin and skin structure infection with single-dose dalbavancin in persons who inject drugs |
| title_full | Treatment of acute bacterial skin and skin structure infection with single-dose dalbavancin in persons who inject drugs |
| title_fullStr | Treatment of acute bacterial skin and skin structure infection with single-dose dalbavancin in persons who inject drugs |
| title_full_unstemmed | Treatment of acute bacterial skin and skin structure infection with single-dose dalbavancin in persons who inject drugs |
| title_short | Treatment of acute bacterial skin and skin structure infection with single-dose dalbavancin in persons who inject drugs |
| title_sort | treatment of acute bacterial skin and skin structure infection with single dose dalbavancin in persons who inject drugs |
| topic | dalbavancin infectious disease intravenous methicillin-resistant Staphylococcus aureus skin infection staphylococcal substance abuse |
| url | https://www.drugsincontext.com/treatment-of-acute-bacterial-skin-and-skin-structure-infection-with-single-dose-dalbavancin-in-persons-who-inject-drugs |
| work_keys_str_mv | AT pedroluisgonzalez treatmentofacutebacterialskinandskinstructureinfectionwithsingledosedalbavancininpersonswhoinjectdrugs AT uraniarappo treatmentofacutebacterialskinandskinstructureinfectionwithsingledosedalbavancininpersonswhoinjectdrugs AT karthikakinapelli treatmentofacutebacterialskinandskinstructureinfectionwithsingledosedalbavancininpersonswhoinjectdrugs AT jennifersmcgregor treatmentofacutebacterialskinandskinstructureinfectionwithsingledosedalbavancininpersonswhoinjectdrugs AT sailajaputtagunta treatmentofacutebacterialskinandskinstructureinfectionwithsingledosedalbavancininpersonswhoinjectdrugs AT michaelwdunne treatmentofacutebacterialskinandskinstructureinfectionwithsingledosedalbavancininpersonswhoinjectdrugs |